How to Name a Pharmaceutical Company: Pharmaceutical Company Names, Drug Naming Strategy, and Phoneme Analysis

Pharmaceutical company naming operates across two entirely different naming systems that must be designed independently: the corporate entity name and the brand names for individual drug products. Most founders approach pharmaceutical naming as if it were technology naming -- prioritizing distinctiveness, domain availability, and trademark position. Those factors matter, but pharma adds a third layer of constraint that no other industry faces: regulatory review bodies with the power to reject names before products can be commercialized.

The three-layer pharmaceutical naming architecture

FDA brand name review: the POCA and DMEPA process

For every New Drug Application (NDA) and Biologics License Application (BLA), the FDA's Office of Prescription Drug Promotion (OPDP) and the Division of Medication Error Prevention and Analysis (DMEPA) conduct independent proprietary name reviews. The DMEPA review is a safety review, not a marketing review. Its mandate is to identify whether the proposed brand name creates a medication error risk -- specifically, look-alike/sound-alike confusion with existing drug names.

The FDA has published databases of medication errors attributable to name confusion. Names that are visually similar (orthographically) or auditorily similar (phonemically) to existing drugs on the market are rejected or required to be modified before approval. Drug names like Celebrex/Celexa, Lamictal/Lamisil, Paxil/Plavix, and Zantac/Xanax have all generated real medication errors; the FDA now proactively screens to prevent new name pairs with similar confusion potential.

The practical implication: pharmaceutical brand names must be developed with a DMEPA-style look-alike/sound-alike screen built into the naming process. A name that passes trademark clearance and is phonemically distinctive from consumer brands may still fail FDA review if it resembles a drug already in use in the same therapeutic category or in a category where co-prescribing is common. Naming agencies that do not conduct medication error screening as part of pharma brand name development are not conducting a pharma-appropriate process.

The USAN Council and INN Protocol

The United States Adopted Name (USAN) Council -- a joint program of the AMA, ASHP, and APhA -- assigns nonproprietary names to active pharmaceutical ingredients in the US. The USAN is almost always identical or very close to the WHO INN. The INN system uses systematic stems: name suffixes and prefixes that indicate drug class and mechanism. The stem "-mab" indicates monoclonal antibody; "-tinib" indicates kinase inhibitor; "-pril" indicates ACE inhibitor; "-sartan" indicates angiotensin II receptor blocker; "-statin" indicates HMG-CoA reductase inhibitor.

These stems are public property and create a powerful secondary identifier for the drug class. They cannot be incorporated into a brand name in ways that mislead prescribers about the drug class. A brand name for an ACE inhibitor that contains "-pril" is not allowed because it would confuse the brand name with the INN stem system. The brand name must be clearly distinguishable from both the INN and from the stem-based naming pattern for the class.

For biotech companies working on biologics, the INN/USAN system adds biological qualifier stems that specify the antibody type, target, and species source. These increasingly long generic names (alirocumab, pembrolizumab, dupilumab) are functional INN designations -- not brand names -- and they form the basis for pharmacovigilance reporting, international prescribing, and generic interchangeability after exclusivity expires. The brand name must exist as a parallel, clearly distinct identifier in all regulatory records.

Corporate name vs drug brand name: why they require separate strategies

Pharmaceutical companies with multiple pipeline assets face a compound naming problem. The corporate entity name needs to communicate scientific credibility to investors, regulatory agencies, potential acquirers, and clinical trial patients who see the sponsor name on consent forms. The drug brand names need to communicate benefit, memorability, and prescriber preference in highly competitive therapeutic categories. These two naming objectives are not the same.

AbbVie's corporate name communicates nothing about what the company does -- and this is deliberate. The name was coined for the AbbVie spinoff from Abbott Laboratories in 2013 specifically to be a blank institutional identity that could hold whatever therapeutic area the pipeline produced. Humira (adalimumab) carries the therapeutic brand equity; AbbVie holds the investor and regulatory identity. The company name does not need to sell the drug. The drug brand name does not need to communicate corporate identity. Conflating the two objectives produces names that fail both purposes.

Look-alike/sound-alike screening in practice

FDA's DMEPA review uses multiple methodologies to assess confusion risk: orthographic similarity (visual similarity of written names), phonetic similarity (how names sound when spoken aloud and over the phone), and contextual similarity (whether the drugs would be used in the same clinical setting or by the same prescribers). Names are tested in simulated prescribing scenarios -- handwritten prescriptions, verbal orders, electronic health record alerts -- to surface confusion risk that is not apparent in a static side-by-side comparison.

The FDA publishes its proprietary name review results, and historical rejected names are accessible for study. Common rejection grounds include: names ending in common drug suffixes (-ol, -in, -an, -ex, -ix) that create visual similarity to existing drugs; names with the same number of syllables and stress pattern as an existing drug in the same category; names using letter combinations that are commonly misread in handwritten prescriptions (e.g., "I" and "l" confusion, "m" and "n" confusion, "e" and "c" confusion in low-quality photocopies).

International regulatory name requirements

Outside the US, drug brand names require separate regulatory submissions. The European Medicines Agency (EMA) conducts its own proprietary name review, and the UK's MHRA has its own process post-Brexit. Japan's PMDA, Canada's Health Canada, and most other major markets conduct independent name reviews. A name cleared by FDA is not automatically cleared globally. Pharmaceutical companies launching international products must plan for the possibility that their primary brand name is not approvable in one or more key markets -- and must have a backup name or a market-specific brand name strategy.

In some markets, a single global brand name is not achievable. Zyban (bupropion for smoking cessation) uses a different brand name from Wellbutrin (bupropion for depression) even in the same market -- same molecule, different brand names, different indications. International brand name strategy requires mapping the regulatory approval landscape for each target market before committing to a single global name.

Phoneme analysis: Pfizer, Johnson and Johnson, Merck, AbbVie, Roche, Novartis, Eli Lilly, AstraZeneca

Drug brand name patterns that create FDA review risk

• Names that overstate or imply efficacy. FDA's OPDP specifically screens for names that suggest the drug is more effective than evidence supports. Names containing "ultra," "max," "pure," "complete," or therapeutic area outcomes (e.g., a name that implies "cured" or "healed") face promotional labeling review challenges before the drug is approved, because the brand name itself becomes a promotional statement on every package insert and label. The brand name must be neutral or aspirational without making an implicit efficacy claim.
• Phoneme overlap with existing drugs in the same therapeutic category. DMEPA screening is most rigorous when the proposed name is similar to an existing drug that would be co-prescribed or that is used in similar patient populations. A name for a new oncology drug that resembles an existing oncology drug creates a higher rejection likelihood than a name that resembles a drug in an unrelated category, because prescribers and pharmacists operating under high cognitive load in oncology settings are more vulnerable to confusion errors.
• INN stem incorporation. Incorporating established INN stems ("-mab," "-tinib," "-pril," "-sartan," etc.) into a brand name conflates the proprietary name with the nonproprietary naming system. Prescribers and pharmacists trained to use INN stems as category identifiers will misinterpret the drug class from the brand name. This is a safety issue, not just a regulatory formality.
• Names that are difficult to transmit in high-error-risk environments. Drug orders transmitted verbally over the phone, in noisy clinical environments, or written by hand under time pressure create conditions where subtle phoneme differences are lost. Names that rely on a single consonant or vowel distinction from an existing drug name -- rather than a structural phoneme difference -- are high-risk regardless of how distinctive they appear in written form.
• Abbreviation collision. Drug names that produce abbreviations identical to existing drug abbreviations or medical shorthand create a separate category of error risk. FDA evaluates abbreviation potential as part of the name review and will request modifications if the natural abbreviation of a proposed brand name conflicts with an established medical abbreviation.

Four pharmaceutical corporate naming profiles

The founder surname structure. Merck, Pfizer, Roche, Eli Lilly, Bayer. Signals institutional permanence and human accountability. Works for companies with long track records where the surname has accumulated decades of scientific equity. For new entrants, a founder surname creates no initial recall advantage unless the founder is independently famous in the scientific community. The succession ceiling is real but manageable if the institution is large enough that the founder's departure does not materially change the brand's meaning.

The coined Latin/Greek root. Novartis, Sanofi, Amgen (AMGen -- Applied Molecular Genetics), Biogen. Signals scientific origin, works across European languages, and creates clean trademark position. The challenge is that the scientific register is now crowded -- most biotech names of the past 30 years have used this approach, and the space is saturated. Differentiation requires either a particularly distinctive phoneme profile or a meaning that is especially resonant with the company's specific science.

The merger compound. AstraZeneca, GlaxoSmithKline (GSK), Bristol-Myers Squibb. Created through combination rather than designed from the start. The architecture is defensible when both predecessor names carry substantial equity, but produces longer names that operate primarily as legal and financial identifiers rather than consumer-facing brands. Drug brand names do the consumer-facing work independently. If you anticipate growth through acquisition, plan for how a combined entity name would be constructed before you need to name it under time pressure.

The coined word with no prior meaning. AbbVie, Zoetis, Alnyam, Regeneron. Maximum trademark cleanness, maximum flexibility for portfolio expansion across therapeutic areas. Requires the most brand investment to attach meaning, but carries no legacy equity constraints when the pipeline strategy changes. Regeneron's name (regenerating neurons -- coined for its neurotrophic factor research origin) has stretched to cover ophthalmology, dermatology, oncology, and COVID-19 treatment; the name held because it is resonant enough to imply biological regeneration broadly without being specific enough to foreclose any particular therapeutic area.